<div id="readability-page-1"><p>Brookstone Capital Management boosted its stake in  AbbVie Inc. (NYSE:ABBV - Free Report) by 25.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 97,713 shares of the company's stock after purchasing an additional 20,100 shares during the period. Brookstone Capital Management's holdings in AbbVie were worth $22,624,000 at the end of the most recent quarter.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>A number of other large investors also recently added to or reduced their stakes in ABBV. Conning Inc. increased its holdings in  AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company's stock worth $35,458,000 after purchasing an additional 12,690 shares during the period.  Dohj LLC grew its position in shares of  AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company's stock worth $802,000 after buying an additional 1,335 shares in the last quarter.  First Hawaiian Bank increased its stake in shares of  AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock worth $1,403,000 after buying an additional 60 shares during the period.  Charles Schwab Trust Co raised its holdings in  AbbVie by 93.4% in the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company's stock valued at $7,434,000 after acquiring an additional 15,502 shares in the last quarter.  Finally, BankPlus Trust Department lifted its stake in  AbbVie by 3.3% in the second quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock worth $5,033,000 after acquiring an additional 855 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds. </p><h2>AbbVie Price Performance</h2><p>AbbVie stock opened at $230.18 on Thursday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market capitalization of $406.81 billion, a P/E ratio of 174.38, a P/E/G ratio of 1.30 and a beta of 0.36. The firm's 50-day moving average is $226.65 and its two-hundred day moving average is $212.00. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. </p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm posted $3.00 earnings per share. The company's quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  Equities analysts predict that  AbbVie Inc. will post 12.31 earnings per share for the current year. </p><h2>AbbVie Increases Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is presently 496.97%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, December 13th. Erste Group Bank lowered AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Raymond James Financial  set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Morgan Stanley lifted their price target on AbbVie from $261.00 to $269.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, December 12th. Finally, Hsbc Global Res upgraded AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued  a Hold rating to the company. Based on data from MarketBeat.com, AbbVie  has an average rating of &#34;Moderate Buy&#34; and an average price target of $245.84.</p><p><b>View Our Latest Stock Analysis on ABBV</b></p><h2>AbbVie Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>See Also</h2><ul><li>Five stocks we like better than AbbVie</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Brookstone Capital Management increased its stake in AbbVie Inc. by 25.9% in Q3, owning 97,713 shares worth $22.6 million. Other investors also adjusted their holdings. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue up 9.1% year-over-year. The company raised its dividend to $1.73 per share. Analysts have mixed ratings, with some upgrading AbbVie to "strong-buy."</p>

AbbVie Inc. $ABBV Shares Purchased by Brookstone Capital Management